Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Unity Biotechnology Inc
UBXCurrent price
1.31 USD
-0.02 USD (-1.50%)
Last closed
1.25 USD
Company
unitybiotechnology.com
ISIN
US91381U1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
19 714 968 USD
Yield for 12 month
-23.84 %
1Y
3Y
5Y
10Y
15Y
UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Address: 285 East Grand Avenue, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.67 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+236 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-19 699 000 USD
Last Year
-1 944 000 USD
Current Quarter
-216 000 USD
Last Quarter
-221 000 USD
Key Figures UBX
1 year
3 years
5 years
10 years
EBITDA
-27 014 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.97 %
PEG Ratio
–
Return On Equity TTM
-84.95 %
Wall Street Target Price
6.67 USD
Revenue TTM
–
Book Value
0.84 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
-35 223 000 USD
Earnings per share
-1.28 USD
Diluted Eps TTM
-1.28 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics UBX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History UBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
20.10.2022
Dividend Date
–
Stock Valuation UBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
29.7906
Price Sales TTM
6.5445
Enterprise Value EBITDA
-0.2324
Price Book MRQ
1.3939
Financials UBX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators UBX
For 52 weeks
1.11 USD
2.26 USD
50 Day MA
1.41 USD
Shares Short Prior Month
310 693
200 Day MA
1.52 USD
Short Ratio
9.32
Shares Short
305 698
Short Percent
1.83 %
BeatStart